The Scientific World Journal / 2014 / Article / Tab 3

Review Article

Efficacy and Safety of Acotiamide for the Treatment of Functional Dyspepsia: Systematic Review and Meta-Analysis

Table 3

Pooled RR of acotiamide versus placebo for nonresponders by Mantel-Haenszel fixed-effect model.

Groups or subgroupsNumber of trials [reference]Number of patientsRR; 95% CI value Test of heterogeneity
value

Overall symptoms2 [16]7680.95; 0.73–1.240.7100.5100%
 50 mg, tid1 [16]2271.46; 0.78–2.730.230NANA
 100 mg, tid2 [16]4310.83; 0.55–1.260.3800.4200%
 300 mg, tid2 [16]4410.90; 0.60–1.340.5900.5900%
PDS2 [16]3960.71; 0.50–1.020.0600.30018%
 50 mg, tid1 [16]1511.22; 0.64–2.340.540NANA
 100 mg, tid2 [16]2060.51; 0.26–0.990.0500.3700%
 300 mg, tid2 [16]2180.61; 0.34–1.100.1000.5600%
EPSa2 [16]3201.76; 0.90–3.450.1000.19035%
 50 mg, tid1 [16]733.89; 0.46–33.170.210NANA
 100 mg, tid2 [16]1841.91; 0.48–7.570.3600.17047%
 300 mg, tid2 [16]1922.31; 0.34–15.740.3900.07070%

aMantel-Haenszel random-effects model.
CI, confidential interval; FD, functional dyspepsia; NA, not applicable; RR, risk ratio; and tid, three times daily.